title: Oxytocin levels in social anxiety disorder.
abstract: Oxytocin is a neuropeptide recently associated with social behavior in animals and humans, but the study of its function in populations with social deficits such as autism, schizophrenia, and social anxiety disorder has only recently begun. We measured plasma oxytocin in 24 patients with Generalized Social Anxiety Disorder (GSAD) and 22 healthy controls using an enzyme-linked immunosorbent assay. There were no significant differences in oxytocin level (pg/mL) between patients (M=163.0, SD=109.4) and controls (M=145.0, SD=52.9, z=0.21, P=0.8). Within the GSAD sample, however, higher social anxiety symptom severity adjusted for age and gender was associated with higher oxytocin level (R2=0.21, beta=0.014, SE=0.006, t=2.18, P=0.04). In addition, dissatisfaction with social relationships was associated with higher oxytocin levels (R2=0.18, beta=-0.20, SE=0.10, t=-2.01, P=0.05). Our data provide preliminary support for a link between social anxiety severity and plasma oxytocin. These findings may suggest a possible role for oxytocin as a facilitator of social behavior, an effect which may not be fully utilized in individuals with severe social anxiety.
authors.affiliation: Department of Economics, Claremont University, Claremont, CA, USA. ehoge@partners.org
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Hoge
authors.forename: Mark H
authors.initials: MH
authors.lastname: Pollack
authors.forename: Rebecca E
authors.initials: RE
authors.lastname: Kaufman
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Zak
authors.forename: Naomi M
authors.initials: NM
authors.lastname: Simon
mesh_terms: D000328:Adult; D000367:Age Factors; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010121:Oxytocin / Q000097:blood*; D010698:Phobic Disorders / Q000097:blood*; D012016:Reference Values; D012720:Severity of Illness Index; D012737:Sex Factors; D012919:Social Behavior; D012931:Social Environment
chemical_list: D010121:Oxytocin
references.citation: Psychol Med. 1999 Jan;29(1):199-212
references.pmid: 10077308
references.citation: Biol Psychiatry. 1999 Apr 1;45(7):931-3
references.pmid: 10202583
references.citation: Psychiatry. 1999 Summer;62(2):97-113
references.pmid: 10420425
references.citation: Behav Neurosci. 1999 Oct;113(5):1071-9
references.pmid: 10571489
references.citation: Nat Rev Neurosci. 2001 Feb;2(2):129-36
references.pmid: 11252992
references.citation: Am J Med Genet. 2001 Jan 8;105(1):53-4
references.pmid: 11424998
references.citation: Psychoneuroendocrinology. 2002 Aug;27(6):651-60
references.pmid: 12084658
references.citation: Horm Behav. 2003 May;43(5):549-53
references.pmid: 12799171
references.citation: Ann N Y Acad Sci. 1992 Jun 12;652:83-101
references.pmid: 1385685
references.citation: Pharmacol Biochem Behav. 1992 Nov;43(3):855-61
references.pmid: 1448480
references.citation: Science. 2005 Apr 8;308(5719):245-8
references.pmid: 15821089
references.citation: Nature. 2005 Jun 2;435(7042):673-6
references.pmid: 15931222
references.citation: Horm Behav. 2005 Dec;48(5):522-7
references.pmid: 16109416
references.citation: Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16096-101
references.pmid: 16249339
references.citation: J Neurosci. 2005 Dec 7;25(49):11489-93
references.pmid: 16339042
references.citation: Endocrinology. 2006 May;147(5):2423-31
references.pmid: 16439458
references.citation: Psychosom Med. 2006 Mar-Apr;68(2):238-45
references.pmid: 16554389
references.citation: J Autism Dev Disord. 2006 Oct;36(7):891-9
references.pmid: 16865550
references.citation: Clin Pract Epidemiol Ment Health. 2006 Oct 11;2:28
references.pmid: 17034623
references.citation: Curr Opin Psychiatry. 2007 Mar;20(2):158-62
references.pmid: 17278915
references.citation: Psychosom Med. 2007 Feb-Mar;69(2):149-57
references.pmid: 17289829
references.citation: Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4670-5
references.pmid: 17360582
references.citation: Psychoneuroendocrinology. 2007 May;32(4):407-10
references.pmid: 17383107
references.citation: Mol Psychiatry. 2008 Oct;13(10):980-8
references.pmid: 17893705
references.citation: Trends Endocrinol Metab. 1996 May-Jun;7(4):126-31
references.pmid: 18406738
references.citation: Pharmacol Biochem Behav. 1990 Sep;37(1):63-9
references.pmid: 2263668
references.citation: Arch Gen Psychiatry. 1985 Jul;42(7):729-36
references.pmid: 2861796
references.citation: Brain Res. 1988 Jan 26;439(1-2):1-10
references.pmid: 3359176
references.citation: Prog Brain Res. 1983;60:101-14
references.pmid: 6198686
references.citation: Arch Gen Psychiatry. 1994 Oct;51(10):782-92
references.pmid: 7524462
references.citation: Endocr Res. 1994 Feb;20(1):79-87
references.pmid: 8168464
references.citation: Psychopharmacol Bull. 1993;29(2):321-6
references.pmid: 8290681
references.citation: Psychiatry Res. 1993 Aug;48(2):107-17
references.pmid: 8416021
references.citation: Arch Gen Psychiatry. 1996 Feb;53(2):137-43
references.pmid: 8629889
references.citation: Physiol Behav. 1996 Nov;60(5):1209-15
references.pmid: 8916173
references.citation: Biol Psychiatry. 1998 Feb 15;43(4):270-7
references.pmid: 9513736
references.citation: Clin Endocrinol (Oxf). 1998 Aug;49(2):209-16
references.pmid: 9828909
references.citation: Psychoneuroendocrinology. 1998 Nov;23(8):819-35
references.pmid: 9924739